Sarepta Therapeutics appeared to be the Corporate Investor, which was created in 1980. The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the Cambridge.
The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2018. The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2019.
The current fund was established by Marwan Fawaz.
The standard case for the fund is to invest in rounds with 1 partaker. Despite the Sarepta Therapeutics, startups are often financed by Rev1 Ventures, Jain Foundation, GFB ONLUS.
The fund has exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Biotechnology, Genetics. Among the various public portfolio startups of the fund, we may underline Lacerta Therapeutics, Myonexus Therapeutics
Related Funds
Fund Name | Location |
Allegiance Capital | California, Huntington Beach, United States |
Greenoaks Capital | California, San Francisco, United States |
Hanfor (Beijing) Capital Management | Beijing, Beijing, China |
HDI Global SE | Germany, Saxony-Anhalt, Schönebeck (Elbe) |
HT Ventures | - |
Huarong Xianfeng Zichan | China, Guangdong, Shenzhen |
Kibbutz Degania Bet | - |
Magnus Capital | - |
MedEdge | - |
Mercatus Capital | Central, Central Region, Singapore |
Normandie Business Angels | Caen, France, Normandy |
Pets.com | California, Pasadena, United States |
SamStella | New York, New York, United States |
Starquest Capital | Beijing, Beijing, China |
SVM Verwaltungsgesellschaft | Germany, Hamburg |
The Chartered Group | Central, Central Region, Singapore |
Torrent Gas | Ahmedabad, Gujarat, India |
Valence Capital Management | New York, New York, United States |
Wuhan Mutual Entertainment Cultural Industry Investment Management | China, Hubei, Wuhan |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
StrideBio | $81M | 16 Mar 2021 | Durham, North Carolina, United States | ||
AavantiBio | $107M | 22 Oct 2020 | Cambridge, Massachusetts, United States |
– StrideBio, Inc. is a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies.
– The company closed a $81.5m Series B funding round.
– Northpond Ventures and Novo Holdings A/S co-led the round with new investors Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and UF Innovate Ventures joining existing investors Hatteras Venture Partners, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
StrideBio | $81M | 16 Mar 2021 | Durham, North Carolina, United States | ||
AavantiBio | $107M | 22 Oct 2020 | Cambridge, Massachusetts, United States |